Human endogenous retrovirus-H long terminal repeat-associating 2: The next immune checkpoint for antitumour therapy

被引：15
作者：
Ying, Honggang [1 ,2 ,3 ,4 ,5 ]
Xu, Jian [1 ,2 ,3 ,4 ,5 ]
Zhang, Xiaozhen [1 ,2 ,3 ,4 ,5 ]
Liang, Tingbo [1 ,2 ,3 ,4 ,5 ]
Bai, Xueli [1 ,2 ,3 ,4 ,5 ]
机构：
[1] Zhejiang Univ, Affiliated Hosp 1, Sch Med, Dept Hepatobiliary & Pancreat Surg, Hangzhou 310003, Zhejiang, Peoples R China
[2] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Zhejiang Prov Key Lab Pancreat Dis, 79 Qingchun Rd, Hangzhou 310003, Zhejiang, Peoples R China
[3] Zhejiang Prov Innovat Ctr Study Pancreat Dis, Hangzhou 310003, Zhejiang, Peoples R China
[4] Zhejiang Prov Clin Res Ctr Study Hepatobiliary &, Hangzhou 310003, Zhejiang, Peoples R China
[5] Zhejiang Univ, Canc Ctr, Hangzhou 310058, Zhejiang, Peoples R China
来源：
EBIOMEDICINE | 2022年 / 79卷
基金：
中国国家自然科学基金;
关键词：
HHLA2; TMIGD2; KIR3DL3; Immune checkpoint; Cancer immunotherapy; B7; FAMILY-MEMBER; CANCER-IMMUNOTHERAPY; PROGNOSTIC-SIGNIFICANCE; CELL-ADHESION; HHLA2; IDENTIFICATION; EXPRESSION; SURVIVAL; IGPR-1; OVEREXPRESSION;
D O I：
10.1016/j.ebiom.2022.103987
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Human endogenous retrovirus-H long terminal repeat-associating 2 (HHLA2) is a newly emerging immune checkpoint that belongs to B7 family. HHLA2 has a co-stimulatory receptor transmembrane and immunoglobulin domain containing 2 (TMIGD2) and a newly discovered co-inhibitory receptor killer cell Ig-like receptor, three Ig domains, and long cytoplasmic tail (KIR3DL3), which endows it with both immunostimulant and immunosuppression functions in cancer development. In this review, we summarize the HHLA2 expression profile in human cancers, its association with cancer prognosis and clinical features, and its dual roles in regulating cancer immune response through up-to-date literatures. Furthermore, we highlight that precision cancer immunotherapy through manipulating HHLA2-KIR3DL3/TMIGD2 interaction is a promising antitumour strategy.
引用
收藏
页数：11
相关论文
共 74 条
  • [1] Targeted immune epitope prediction to HHLA2 and MAGEB5 protein variants as therapeutic approach to related viral diseases
    Achinko, Daniel A.
    Dormer, Anton
    Narayanan, Mahesh
    Norman, Elton F.
    [J]. BMC IMMUNOLOGY, 2021, 22 (01)
  • [2] Cell adhesion molecule IGPR-1 activates AMPK connecting cell adhesion to autophagy
    Amraei, Razie
    Alwani, Tooba
    Ho, Rachel Xi-Yeen
    Aryan, Zahra
    Wang, Shawn
    Rahimi, Nader
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2020, 295 (49) : 16691 - 16699
  • [3] LAG3 (CD223) as a cancer immunotherapy target
    Andrews, Lawrence P.
    Marciscano, Ariel E.
    Drake, Charles G.
    Vignali, Dario A. A.
    [J]. IMMUNOLOGICAL REVIEWS, 2017, 276 (01) : 80 - 96
  • [4] CD137 (4-1BB) Costimulation Modifies DNA Methylation in CD8+ T Cell-Relevant Genes
    Angela Aznar, M.
    Labiano, Sara
    Diaz-Lagares, Angel
    Molina, Carmen
    Garasa, Saray
    Azpilikueta, Arantza
    Etxeberria, Inaki
    Sanchez-Paulete, Alfonso R.
    Korman, Alan J.
    Esteller, Manel
    Sandoval, Juan
    Melero, Ignacio
    [J]. CANCER IMMUNOLOGY RESEARCH, 2018, 6 (01) : 69 - 78
  • [5] KIR3DL3 Is an Inhibitory Receptor for HHLA2 that Mediates an Alternative Immunoinhibitory for Pathway to PD1
    Bhatt, Rupal S.
    Berjis, Abdulla
    Konge, Julie C.
    Mahoney, Kathleen M.
    Klee, Alyssa N.
    Freeman, Samuel S.
    Chen, Chun-Hau
    Jegede, Opeyemi A.
    Catalano, Paul J.
    Pignon, Jean-Christophe
    Sticco-Ivins, Maura
    Zhu, Baogong
    Hua, Ping
    Soden, Jo
    Zhu, Jie
    McDermott, David F.
    Arulanandam, Antonio R.
    Signoretti, Sabina
    Freeman, Gordon J.
    [J]. CANCER IMMUNOLOGY RESEARCH, 2021, 9 (02) : 156 - 169
  • [6] HHLA2 is expressed in pancreatic and ampullary cancers and increased expression is associated with better post-surgical prognosis
    Boor, Patrick P. C.
    Sideras, Kostandinos
    Biermann, Katharina
    Aziz, M. Hosein
    Levink, Iris J. M.
    Mancham, Shanta
    Erler, Nicole S.
    Tang, Xudong
    van Eijck, Casper H.
    Bruno, Marco J.
    Sprengers, Dave
    Zang, Xingxing
    Kwekkeboom, Jaap
    [J]. BRITISH JOURNAL OF CANCER, 2020, 122 (08) : 1211 - 1218
  • [7] The clinical significance of HERV-H LTR -associating 2 expression in cervical adenocarcinoma
    Byun, Jung Mi
    Cho, Hwa Jin
    Park, Ha Young
    Lee, Dae Sim
    Choi, In Hak
    Kim, Young Nam
    Jeong, Chul Hoi
    Kim, Da Hyun
    Hwa Im, Do
    Min, Byoung Jin
    Lee, Kyung Bok
    Sung, Moon Su
    Jeong, Dae Hoon
    [J]. MEDICINE, 2021, 100 (01) : E23691
  • [8] Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1
    Champiat, Stephane
    Dercle, Laurent
    Ammari, Samy
    Massard, Christophe
    Hollebecque, Antoine
    Postel-Vinay, Sophie
    Chaput, Nathalie
    Eggermont, Alexander
    Marabelle, Aurelien
    Soria, Jean-Charles
    Ferte, Charles
    [J]. CLINICAL CANCER RESEARCH, 2017, 23 (08) : 1920 - 1928
  • [9] Upregulated immune checkpoint HHLA2 in clear cell renal cell carcinoma: a novel prognostic biomarker and potential therapeutic target
    Chen, Dongming
    Chen, Wei
    Xu, Yong
    Zhu, Meng
    Xiao, Yi
    Shen, Yanhao
    Zhu, Shuai
    Cao, Changchun
    Xu, Xianlin
    [J]. JOURNAL OF MEDICAL GENETICS, 2019, 56 (01) : 43 - 49
  • [10] Overexpression of HHLA2 in human clear cell renal cell carcinoma is significantly associated with poor survival of the patients
    Chen, Lujun
    Zhu, Dawei
    Feng, Jun
    Zhou, You
    Wang, Qi
    Feng, Huijing
    Zhang, Junping
    Jiang, Jingting
    [J]. CANCER CELL INTERNATIONAL, 2019, 19 (1)
12345678